Atossa Therapeutics, Inc. (ATOS)
Atossa Therapeutics, Inc.
107 Spring Street
Seattle, WA 98104
United States
206 588 0256
https://www.atossatherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President | 1.21M | N/A | 1951 |
| Ms. Heather Rees CPA | Senior VP of Finance & Principal Accounting Officer | 520.64k | N/A | 1973 |
| Ms. Delly Behen P.H.R. | Senior Vice President of Administration & HR | N/A | N/A | N/A |
| Mr. Eric Van Zanten | Vice President of Investor & Public Relations | N/A | N/A | N/A |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer | N/A | N/A | N/A |
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Corporate governance
Atossa Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
